Evidence map›Paper›PMID 25655068›Full record

ArticleJournal of the American Society of Nephrology : JASN2015

Inflammation-Induced IL-6 Functions as a Natural Brake on Macrophages and Limits GN.

Michael Luig, Malte A Kluger, Boeren Goerke, Matthias Meyer, Anna Nosko, Isabell Yan, Jürgen Scheller, Hans-Willi Mittrücker, Stefan Rose-John, Rolf A K Stahl and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 81 citations in OpenAlex.

  1. Review
  2. Article
  3. Identification of a Novel Peptide fromFoods (Basel, Switzerland) · 2025
    Article
  4. Review
  5. Progress of ADAM17 in Fibrosis-Related Diseases.Mediators of inflammation · 2025
    Review
  6. Article
  7. Article
  8. IL-6 and diabetic kidney disease.Frontiers in immunology · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Journal of fungi (Basel, Switzerland) · 2021
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Michael LuigMedical Clinic III and.
Malte A KlugerMedical Clinic III and.
Boeren GoerkeMedical Clinic III and.
Matthias MeyerMedical Clinic III and.
Anna NoskoMedical Clinic III and.
Isabell YanImmunology Institute, Hamburg University Medical Center, Hamburg, Germany;
Jürgen SchellerInstitute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; and.
Hans-Willi MittrückerImmunology Institute, Hamburg University Medical Center, Hamburg, Germany;
Stefan Rose-JohnInstitute of Biochemistry, Christian-Albrechts-University, Kiel, Germany.
Rolf A K StahlMedical Clinic III and.
Ulf PanzerMedical Clinic III and.
Oliver M SteinmetzMedical Clinic III and o.steinmetz@uke.de.
Universität Hamburg · DEHeinrich Heine University Düsseldorf · DEKiel University · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IL-6 can mediate proinflammatory effects, and IL-6 receptor (IL-6R) blockade as a treatment for inflammatory diseases has entered clinical practice. However, opposing effects of IL-6 have been observed in models of GN. Although IL-6 is proinflammatory in murine lupus nephritis, protective effects have been observed for IL-6 in the nephrotoxic nephritis (NTN) model of acute crescentic GN. In light of the potential dangers of IL-6-directed treatment, we studied the mechanisms underlying the contradictory findings in GN. IL-6 can signal through the membrane-bound IL-6R, which is expressed only on hepatocytes and certain leukocytes (classic), or through the soluble IL-6R, which binds the ubiquitously expressed gp130 (alternative). Preemptive treatment of mice with anti-IL-6R or anti-IL-6 worsened NTN, whereas selective blockade of alternative IL-6 signaling by the fusion protein sgp130Fc did not. FACS analysis of mouse spleen cells revealed proinflammatory macrophages express the highest levels of IL-6Rα, and in vitro treatment with IL-6 blocked macrophage proliferation. Furthermore, proinflammatory macrophages were expanded during inflammation in IL-6(-/-) mice. Late application of anti-IL-6 after establishment of adaptive nephritogenic immunity was sufficient to aggravate NTN within 2.5 days, a period when macrophages are active. Finally, NTN was aggravated in mice with macrophage-specific impairment of IL-6 classic signaling, coincident with enhanced macrophage proliferation and accumulation in the kidney. Our data thus reveal a novel mechanism in which IL-6-mediated dampening of macrophage activation protects tissues from overshooting immune responses. This finding has important implications for potential IL-6-directed therapies and supports the careful choice of recipient patients and timing.

Indexed as

Analysis of VarianceAnimalsCell ProliferationCells, CulturedDisease Models, AnimalFlow CytometryGlomerulonephritisImmunohistochemistryInterleukin-6MacrophagesMaleMiceMice, Inbred C57BLMice, KnockoutRandom AllocationReal-Time Polymerase Chain ReactionInterleukin-6Receptors, Interleukin-6cytokinesGNimmunologypathology

Identifiers

PMID25655068
PMCPMC4483592
OpenAlexW2102768377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.